EURETINA 2017: Genentech Ophthalmology Data Highlights

Source: Genentech

Genentech released teh data it will be presenting at the European Society of Retina Specialists (EURETINA) meeting on September 7-10 in Barcelona.

Below are key takeaways from the EURETINA 2017 studies:

“Understanding The Natural History Of Geographic Atrophy Secondary To Age-Related Macular Degeneration: Baseline Data From Proxima A” – Presented by Jordi Monés, M.D., PhD

Thursday, September 7, 8:36 a.m.; Free Paper Session 3: AMD I, Room: 118

  • Proxima A is an observational study designed to help researchers better understand the relationship between disease progression and visual function in patients with GA.
  • A planned interim analysis of baseline patient characteristics was consistent with expectations per study enrollment. Baseline visual function data demonstrated the presence of significant functional deficits, highlighting the potential severity and impact of GA on patients’ quality of life.

“Analysis Of The Serum And Aqueous Humor Levels Of Interleukin 6 (IL-6) In Patients With Neovascular (Wet) Age-Related Macular Degeneration (nAMD) Receiving Anti-Vascular Endothelial Growth Factor A (VEGF) Monotherapy” – Presented by Ivaylo Stoilov, M.D.

Friday, September 8, 9:18 a.m.; Free Paper Session 9: AMD III, Room 117

  • In this analysis from the Phase III HARBOR trial of ranibizumab in wet AMD, the objectives were to measure and compare IL-6 levels in participants who had matching aqueous humor and serum samples and to describe vision outcomes in these same patients.
  • In this sample of HARBOR trial participants with wet AMD, aqueous levels of IL-6 exhibited a significantly broader distribution compared to serum levels. There was no correlation between aqueous and serum IL-6 levels.
  • Trial participants with the highest aqueous IL-6 levels on average lost 9 BCVA letters by the end of the study.

“Key Clinical Pearls of the Use of Ranibizumab in the Treatment of Pigment Epithelial Detachments in Eyes With Neovascular Age-Related Macular Degeneration: Results From HARBOR” – Presented by Patricio Schlottmann, M.D.

Friday, September 8, 5:06 p.m.; Free Paper Session 14: AMD IV, Room 111

  • This presentation summarizes key critical findings relating to the optimal treatment of eyes with wet AMD and pigment epithelial detachments (PED) based on data from the Phase III HARBOR study.
  • The study found that monthly or as needed (PRN) treatment with ranibizumab for wet AMD and PED was safe and effective.

“The Fate of 47/53: Regression of Diabetic Retinopathy With Ranibizumab in Patients With Diabetic Macular Edema & Highest-Risk Non-Proliferative Diabetic Retinopathy – Presented by Patricio G. Schlottmann, M.D.

Saturday, September 9, 5:24 p.m.; Free Paper Session 19: Vascular Diseases & Diabetic Retinopathy V, Room 120

  • In this post-hoc analysis of the Phase III RIDE/RISE trials, the effects of ranibizumab were assessed in eyes with moderately severe or severe non-proliferative DR (NPDR) at baseline – the group at highest risk of progression to proliferative DR.
  • More than 75 percent of patients treated monthly with ranibizumab saw a significant improvement in their DR compared to less than 12 percent of sham-treated patients at two years. 

“Sustained Delivery of Ranibizumab: The LADDER Trial of the Ranibizumab Port Delivery System” – Presented by Giulio Barteselli, M.D.

e-Poster Available September 7-10; Poster Village

  • This presentation outlines details of the LADDER trial, a Phase II study designed to evaluate the safety and efficacy of the ranibizumab port delivery system (RPDS), an implanted device that provides sustained intravitreal release of ranibizumab, in patients with wet AMD.
  • Patients eligible for the LADDER trial have wet AMD, have been diagnosed within 6 months and have a documented response to anti-VEGF treatment.
  • Researchers believe sustained delivery of ranibizumab via the RPDS has the potential to achieve less frequent dosing compared with anti-VEGF injections and improve on visual outcomes associated with under-treatment in clinical practice.

“Assessing The Usability Of The Ranibizumab 0.5 mg Prefilled Syringe (PFS) By Healthcare Professionals In The US” – Presented by Andrew Antoszyk, M.D.

e-Poster Available September 7-10; Poster Village

  • The purpose of these studies was to evaluate the usability (both simulated and actual) of the ranibizumab PFS by assessing if U.S. healthcare professionals could successfully prepare and perform intravitreal injections using the ranibizumab PFS without prior training, using only the Instructions for Use and U.S. Prescribing Information.
  • All participants successfully performed all essential and safety-critical tasks without use errors in both the simulated-use and actual-use studies.
  • The authors suggest the ease-of-use, time savings achieved and reduced risk of contamination associated with ranibizumab PFS may represent significant benefits for health care providers and patients in real world clinical settings.

“Living With Geographic Atrophy: An Ethnography Study” – Presented by Sobha Sivaprasad, M.D.

e-Poster Available September 7-10; Poster Village

  • This study used ethnography to assess the lived experience of 16 people with GA residing in the United States, United Kingdom and Germany.
  • The study found that all patients reported that GA negatively impacted activities of daily living, including reading, driving, recognizing faces, and performing household chores. Participants also reported financial and social impacts.
  • In addition, participants reported similar functional impacts across domains regardless of their best-corrected visual acuity (BCVA), suggesting that BCVA may not fully capture the impact of GA from the patient’s perspective.

Related Content